To study the effect of Durvadi Ghrita uttarabasti (a local treatment through vagina) and oral administration of Indrayava Choorna in management of excessive and irregular uterine bleeding.
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: N921- Excessive and frequent menstruation with irregular cycle
- Registration Number
- CTRI/2020/11/029183
- Lead Sponsor
- Dr Taware Smritika Mohanrao
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Married women
2.All patients with complaints of excessive bleeding during menstruation , irregularly irregular bleeding due to DUB, uterine fibroid less than 3cm and adenomyosis.
3.Mild, moderate and severe yonigata Raktasrava wiith sarvadehik lakshanas.
4.Patients with Raktapradar for a period of 2-3 cycles.
Exclusion Criteria
1.Raktapradar with asadhya lakshanas.
2.patients suffeering from uterine fibroid more than 3cm, large ovarian cyst ,uterine or cervical malignancy, Yoni Arsha i.e cervical polyp.
3.Per vaginal bleeding due to trauma.
4.Patients suffering from blood dyscrasias.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the effect of Durvadi Ghrita Uttarbasti and oral administration of Indrayava choorna on Raktapradar.Timepoint: Durvadi Ghrita Uttarbasti will be done for 3 consecutive days when bleeding stops in 3 to 5 ml of dose, along with this oral administration of Indrayava choorna for 7 days in 6gm BD dose irrespective of bleeding will be given. ( assesment will be done per month for 3 months)
- Secondary Outcome Measures
Name Time Method 1.To study clinically the role of Raktapitta chikitsa in treatment of Raktapradar. <br/ ><br>2.To study literary aspect of Rakta Pradara according to Ayurveda. <br/ ><br>3.To note adverse reactions of the formulations and procedure if any. <br/ ><br>4.To study the effect of treatment on bleeding in DUB ,fibroid uterus and adenomyosis. <br/ ><br>5.Recurrence of disease and apunarbhav chikitsa will be observed .Timepoint: Duration of study is 3 months. <br/ ><br>1st follow up will be taken after 15 days. <br/ ><br>2nd follow up will be taken after next menses assessment will be done and treatment will be continued even if there is reduction in signs and symptoms. <br/ ><br>3rd follow up after next menses if there is substantial reduction in symptoms treatment will be discontinued or else repeated for third cycle also.